Elusys Therapeutics, Inc., published data on Thursday on more than 450 healthy adult subjects from five clinical trials used to support recent U.S. Food and Drug Administration (FDA) marketing approval of ANTHIM injection.
ANTHIM is used in adult and pediatric patients for the treatment of inhaled anthrax due to Bacillus anthracis in combination with antibacterial drugs. The treatment is used for prophylaxis of inhaled anthrax when alternative therapies are not available or appropriate.
ANTHIM is a monoclonal antibody that binds to the protective antigen component of anthrax toxin. The treatment’s anthrax-neutralizing activity prevents entry of anthrax toxin into susceptible cells, avoiding any further spread of the toxin throughout the body and ensuing tissue damage. The treatment is supplied as a single-dose vial for IV-infusion.
Elusys was awarded a $45 million delivery order from the U.S. government in November to supply ANTHIM for the U.S. Strategic National Stockpile. The ANTHIM program was supported primarily by the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and the Biomedical Advanced Research and Development Authority.
The results from the studies were published online in the journal Clinical Therapeutics.
Elusys Therapeutics develops antibody therapeutics for the treatment of various infectious diseases.
The ByteDance-owned TikTok faces an uphill battle in the United States after President Joe Biden…
Promising to grow space for integrating and delivering on critical defense programs by more than…
In unsealing a 13-page indictment this week, the U.S. Department of Justice (DOJ) revealed charges…
A bill targeting the illicit fentanyl supply chain, the Fentanyl Eradication and Narcotics Deterrence (FEND)…
In order to move the state closer to federal standards and allow reporting of local…
For the next round of participants in a pilot program to Accelerate the Procurement and…
This website uses cookies.